DTC Mission

"Help raise awareness and provide funding
for the research of rare kidney cancers like HLRCC
in children and young adults."

 

“I am personally experiencing the effects of rare kidney cancer (HLRCC) and I have seen the effects on others who are also being treated. More research is needed to help them and their families so institutions (like National Cancer Institute at NIH, Yale Smilow Cancer Center, Georgetown Lombardi Cancer Center, and David Geffen School of Medicine at UCLA) can continue to help those who suffer from rare kidney cancers. With this continued collaboration from these institutions, we are growing closer to new cures.”
-Andrew Lee

 

Please find our collection of HLRCC specific information and links at the bottom of this page.
We will be updating this constantly as we come across more ground breaking research.


RECOGNITION & AWARDS

FNIH 2018 Charles A. Sanders, M.D. Partnership Award

NIH Cancer Patient Receives Humanitarian Award

BASF Customer Andrew Lee & Driven To Cure Receive Award

Memorial Tribute from The State of Maryland - Presented personally by
The First Lady of Maryland Yumi Hogan

Memorial Tribute from The General Assembly of Maryland

 
Lee_Tribute_Governor_web.jpg
Lee_Tribute_Aseembly_web.jpg
 

BOARD MEMBERS

Andrew H. Lee, Director, 
President & CEO, Driven to Cure, INC
Bruce H. Lee, Director, 
Chairman, Treasurer & Secretary of Driven to Cure, (President & CEO, LDG INC)
Daniel J. Bihlmeyer, Director,
(North America Marketing Director,
BASF Automotive Refinish)

Patrick F. Greaney, Director,
(Attorney, Furey, Doolan & Abell, LLP)
James P. Martinko, Director,
(Office Managing Partner CPA, CohnReznick LLP)
Harvey Goodman, Director,
(President, Goodman-Gable-Gould)
Kenneth R. Kennerly, Director,
(Executive Director The Honda Classic)
Ronald D. Paul, Director,
(Chairman/CEO EagleBank) 
Creative Director
Max Vandenberg
Photography & Video
Tommy F. Lee (Crustless Media)

FCancerBASF2.jpg
20161102_115648.jpg
received_1315671795112666.jpeg
20161005_214828.jpg
 

HLRCC Specific Information and Links

HLRCC - A rare inherited disorder that increases the risk of developing benign (not cancer) lesions of the skin and the uterus (leiomyomas) and malignant (cancer) tumors of the uterus (leiomyosarcoma) and the kidney. Also called hereditary leiomyomatosis and renal cell cancer syndrome.